SYL-1801 is under clinical development by Sylentis SAU and currently in Phase II for Choroidal Neovascularization. According to GlobalData, Phase II drugs for Choroidal Neovascularization have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SYL-1801’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SYL-1801 overview
SYL-1801 is under development for the treatment of wet form of neovascular age related macular degeneration, diabetic retinopathy and choroidal neovascularization. It is administered by ophthalmic routes. The drug candidate is a siRNA developed which is being based on SIRFINDER technology.
Sylentis SAU overview
Sylentis SAU (Sylentis), a subsidiary of Pharma Mar SA, is a biotechnology company that researches and develops new medicaments based on RNA interference gene silencing technology. The company develops products, which include bamosiran and SYL1001. It offers products for various therapeutic areas such as glaucoma, ocular allergies, dry eye syndrome and neurodegenerative diseases. Sylentis also conducts research on ophthalmology, inflammation, central nervous system, formulations and medications. The company collaborates with various pharmaceutical companies and institutions to markets its products. Sylentis is headquartered in Madrid, Spain.
For a complete picture of SYL-1801’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
